Amylin, Lilly, and Alkermes Await FDA Decision on Byetta for Diabetes
March 10, 2010 by tim · Leave a Comment
On February 25th, 2010, Amylin, Lilly, and Alkermes announced in a press release that the FDA had set March 12th 2010 as the Prescription Drug User Fee Act (PDUFA) action date for Byetta’s long acting formulation – exenatide once weekly. Our readers will recall that Byetta is used by type 2 diabetics for glycemic (blood glucose) control and [...]